Alk­er­mes CEO Pops stays fo­cused on 5461 fil­ing plans; Shkre­li gets booed at Har­vard

• Alk­er­mes $ALKS is mov­ing ahead with plans to file a new de­pres­sion drug, ALKS-5461, lat­er in the year. “This is a fast-track des­ig­nat­ed med­i­cine,” CEO Richard Pops told an­a­lysts in Wednes­day’s quar­ter­ly call. “As we’ve done through­out the de­vel­op­ment process, ear­li­er this week we met with FDA for a Type C sci­en­tif­ic ex­change to share with them the da­ta from FOR­WARD-5. The meet­ing with FDA was pro­duc­tive, and we are on track with the plan sub­mis­sion of the NDA in the sec­ond half of the year.” And he is push­ing ahead with a care­ful eye on ALKS-3831, “which is com­ing in­to fo­cus as the piv­otal pro­gram ma­tures.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER